Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of May 2023. The report, dated May 10, 2023, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a press release rather than a detailed financial statement.
Material Changes
The filing text does not contain data regarding material changes versus prior comparable periods. The specific content of the referenced press release is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These details are contained within the incorporated Exhibit 99.1, which is not present in the source text.
Key Facts for Investor Verification
- Verify the content of the press release dated May 10, 2023 (Exhibit 99.1), as the specific news or event triggering this filing is not described in the cover page text.
- Confirm the company's current cash position and burn rate, as no financial metrics are disclosed in this specific filing.
- Review the registration statement on Form F-3 (File No. 333-252074) to understand how this report is incorporated by reference.